Effect of background insulin therapy on cardiovascular outcomes with SGLT-2 inhibitors in type 2 diabetes: A Meta-analysis of Cardiovascular Outcome Trials

Cardiovascular (CV) benefits of SGLT-2 inhibitors (SGLT-2i) have been consistent in type 2 diabetes mellitus (T2DM). To find whether SGLT-2i show similar CV effects with insulin therapy in T2DM, we conducted a trial-level meta-analysis of CV outcome trials. This meta-analysis found SGLT-2i exert CV benefit, irrespective of background insulin therapy.

Source: Diabetes Research and Clinical Practice - January 6, 2021 Category: Endocrinology Authors: Awadhesh Kumar Singh, Ritu Singh Source Type: research